Overview

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
0
Participant gender:
All
Summary
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Lopinavir
Ritonavir
Criteria
Inclusion Criteria:

- HIV Infected subjects

- Subjects failing in current HIV treatment, or

- Subjects with a viral load < 400 copies/mL and not tolerating their current HIV
treatment.

Exclusion Criteria:

- Subject is currently participating in another clinical study or has participated in
another clinical study within 30 days prior to screening visit

- Subject is pregnant